Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

You'd hardly know it with the recent streak of summer weather, but we're weeks away from colder days when respiratory viruses ...

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...

Thanks to mass immunization campaigns, by the year 2000, measles, once a common childhood illness with severe complications, ...

The modified vaccinia Ankara-Bavarian Nordic mpox vaccine (MVA-BN; Jynneos) generated robust immune responses in adolescents ...

A vaccine against fentanyl—yes! Finally, a truly novel approach to SUDs is currently under development and hopefully will ...